Modulation of antioxidant enzymes p21(WAF1) and p53 expression during proliferation and differentiation of human melanoma cell lines

Free Radical Biology and Medicine

Volumn 26, Issue 7-8, 1999, Pages 1027-1033

  Bravard, A ^a   Petridis, F ^a   Luccioni, C ^a  

^a CEA/DSV/DRR   (France)

Author keywords

Antioxidant enzymes; Differentiation; Glutathione; Human; Melanoma; p21(WAF1); p53; Proliferation

Indexed keywords

CATALASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; MELANIN; MONOPHENOL MONOOXYGENASE; PROTEIN P21; PROTEIN P53; SUPEROXIDE DISMUTASE;

ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CATALASE; CELL DIFFERENTIATION; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GLUCOSEPHOSPHATE DEHYDROGENASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; KINETICS; MELANOMA; MONOPHENOL MONOOXYGENASE; SUPEROXIDE DISMUTASE; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032896822     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(98)00299-8     Document Type: Article

References (35)

1. Armstrong B.K., English D.S. Cutaneous malignant melanoma. Schottenfeld D., Fraumeni J.F. Cancer epidemiology and prevention. 1996;1282-1312 Oxford University Press, Oxford.
2. Hansson J. Systemic therapy of malignant melanoma. Med. Oncol. 14:1997;73-81.
3. Burdon R.H. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic. Biol. Med. 18:1995;775-794.
4. Bize I.B.B., Oberley L.W., Morris H.P. Superoxide dismutase and superoxide radical in Morris hepatomas. Cancer Res. 40:1980;3686-3693.
5. Oberley L.W., Oberley T.D. Role of anti-oxidant enzymes in cell immortalization and transformation. Mol. Cell. Biochem. 84:1988;147-153.
6. Galeotti T., Wohlbar H., Borrello S., De Leo M.E. Messenger RNA for manganese and copper-zinc superoxide dismutase in hepatomas correlation with degree of differentiation . Biochem. Biophys. Res. Commun. 165:1989;581-589.
7. Allen R.G. Oxygen-reactive species and antioxidant responses during development the metabolic paradox of cellular differentiation . Proc. Soc. Exp. Biol. Med. 196:1991;117-129.
8. Nishida S., Akai F., Iwasaki H., Hosokawa K., Kusunoki T., Suzuki K., Taniguchi N., Hashimoto S., Tamura T.T. Manganese superoxide dismutase content and localization in human thyroid tumors. J. Pathol. 169:1993;341-345.
9. Bravard A., Beaumatin J., Dussaulx E., Lesuffleur T., Zweibaum A., Luccioni C. Modifications of the anti-oxidant metabolism during proliferation and differentiation of colon tumor cell lines. Int. J. Cancer. 59:1994;843-847.
10. Bravard, A.; Cherbonnel-Lasserre, C.; Reillaudou, M.; Beaumatin, J.; Dutrillaux, B.; Luccioni, C. Modifications of the antioxidant enzymes in relation with chromosome imbalances in human melanoma cell lines. Melanoma Res. (In press).
11. Church S.L., Grant J.W., Ridnour L.A., Oberley L.W., Swanson P.E., Meltzer P.S., Trent J.M. Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc. Natl. Acad. Sci. USA. 90:1993;3113-3117.
12. St. Clair D.K., Oberley T.D., Muse K.E., St. Clair W.H. Expression of manganese superoxide dismutase promotes cellular differentiation. Free Radic. Biol. Med. 16:1994;275-282.
13. Li J.J., Oberley L.W., St. Clair D.K., Ridnour L.A., Oberley T.D. Phenotypic changes induced in human breast cancer cells by overexpression of manganese-containing superoxide dismutase. Oncogene. 10:1995;1989-2000.
14. Yan T., Oberley L.W., Zhong W., St. Clair D.K. Manganese-containing superoxide dismutase overexpression causes phenoptypic reversion in SV40-transformed human lung fibroblasts. Cancer Res. 56:1996;2864-2867.
15. Liu R., Oberley T.D., Oberley L.W. Transfection and expression of MnSOD cDNA decreases tumor malignancy of human oral squamous carcinoma SCC-25 cells. Hum. Gene Ther. 8:1997;585-595.
16. Zhong W., Oberley L.W., Oberley T.D., St. Clair D.K. Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oncogene. 14:1997;481-490.
17. Thrall B.D., Raha G.A., Springer D.L., Meadows G.G. Differential sensitivity of murine melanocytes and melanoma cells to buthionine sulfoximine and anticancer drugs. Pigment Cell Res. 4:1991;234-239.
18. Revesz L., Edgren M.R., Wainson A.A. Selective toxicity of buthionine sulfoximine (BSO) to melanoma cells in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys. 29:1994;403-406.
19. Palomares T., Alonso-Varona A., Alvarez A., Castro B., Calle Y., Bilbao P. Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells. Clin. Exp. Metastasis. 15:1997;329-337.
20. Del Marnol V., Solano F., Sels A., Huez G., Libert A., Lejeune F., Ghanem G. Glutathione depletion increases tyrosinase activity in human melanoma cells. J. Invest. Dermatol. 101:1993;871-874.
21. Bustamante J., Guerra L., Bredeston L., Mordoh J., Boveris A. Melanin content and hydroperoxide metabolism in human melanoma cells. Exp. Cell Res. 196:1991;172-176.
22. Jiang H., Lin J., Su Z.Z., Herlyn M., Kerbel R.S., Weissman B.E., Welch D.R., Fisher P.B. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene. 10:1995;1855-1864.
23. Yang Z.Y., Perkins N.D., Ohno T., Nabel E.G., Nabel G.J. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Med. 1:1995;1052-1056.
24. Kickina J., Green A., Rauth S. Tumor suppressor p53 down-regulates tissue-specific expression of tyrosinase gene in human melanoma cell lines. Pigment Cell Res. 9:1996;85-91.
25. Menon I.A., Wakeman D.C., Persad S.D., Avaria M., Trope G.E., Basu P.K. Quantitative determination of the melanin contents in ocular tissues from human blue and brown eyes. J. Ocular Pharmacol. 8:1992;35-42.
26. Kiguchi F.R., Collart C., Henning-Chubb C., Huberman E. Induction of cell differentiation in melanoma cells by inhibitors of IMP dehydrogenase altered patterns of IMP dehydrogenase expression and activity . Cell Growth Differ. 1:1990;259-270.
27. Bravard A., Hoffschir F., Sabatier L., Ricoul M., Pinton A., Cassingena R., Estrade S., Luccioni C., Dutrillaux B. Early superoxide-dismutase alterations during SV40-transformation of human fibroblasts. Int. J. Cancer. 52:1992;797-801.
28. Bravard A., Hoffschir F., Ricoul M., Cassingena R., Estrade S., Luccioni C., Dutrillaux B. Alterations of the glutathione-cycle enzymes during and after SV40-transformation of human fibroblasts. Carcinogenesis. 14:1993;21-24.
29. Aebi H. Catalase in vitro. Methods Enzymol. 105:1984;121-126.
30. Anderson M.E. Tissue glutathione. Greenwald R.A. Handbook of methods for oxygen radical research. 1985;317-323 CRC Press, Boca Raton.
31. Cip1/WAF1/Sdi1 . J. Pathol. 183:1997;134-140.
32. Trotter M.J., Tang L., Tron V.A. Overexpression of the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) in human cutaneous malignant melanoma. J. Cutan. Pathol. 24:1997;265-271.
33. Vidal M.J., Loganzo A.R., de Oliveira N.K., Albino A.P. Mutations and deffective expression of the WAF1p21 tumour-suppressor gene in malignant melanomas. Melanoma Res. 5:1995;243-250.
34. Strech J.R., Gatter K.C., Ralfkiaer E., Lane D.P., Harris A.L. Expression of mutant p53 in melanoma. Cancer Res. 51:1991;5976-5979.
35. Weiss J., Schwechheimer K., Cavenee W.K., Herlyn M., Arden K.C. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int. J. Cancer. 54:1993;693-699.